|FGFR2_HUMAN » Fibroblast growth factor receptor 2 » FGFR-2; K-sam;KGFR; Keratinocyte growth factor receptor;|
|Hydrophobic Thickness||30.0 ± 4.6 Å|
|Tilt Angle||1 ± 0°|
|Links||UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC, HMDB|
|TM Segments||373-400 (373-401)|
Immune System (Reactome)
MAPK signaling pathway (KEGG)
Pathways in cancer (KEGG)
PI3K-Akt signaling pathway (KEGG)
Prostate cancer (KEGG)
Signal Transduction (Reactome)
|PDB||3dar (146-249), 1wvz (147-249), 3ri1 (458-768), 2pvy (A/B/C/D=458-768), 4j99 (A/B/C/D=458-768), 4j95 (A/B/C/D=458-768), 4j97 (A/B/C/D=458-768), 3euu (A/B=150-249), 2psq (A/B=413-768), 3b2t (A/B=458-766), 4j96 (A/B=458-768), 2q0b (A/B=458-768), 4j98 (A/B=458-768), 2pzr (A/B=458-768), 2pzp (A/B=458-768), 2pz5 (A/B=458-768), 2py3 (A/B=458-768), 2pwl (A/B=458-768), 3cu1 (A/C=150-249), 4j23 (A=147-366), 3caf (A=150-249), 1djs (A=32-362), 1oec (A=456-768), 1gjo (A=456-768), 3cly (A=458-778), 2pvf (A=458-778, B=764-778), 1e0o (B/D=148-366), 3ojm (B=140-313), 1nun (B=140-368), 3oj2 (C/D=140-313), 1iil (E/F/G/H=147-366), 1ii4 (E/F/G/H=147-366), 1ev2 (E/F/G/H=147-366), 2fdb (P/R=149-368)|
|UniProt annotation for FGFR2_HUMAN » Fibroblast growth factor receptor 2|
|FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1. CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. ENZYME REGULATION: Present in an inactive conformation in the absence of bound ligand. Ligand binding leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by ARQ 523 and ARQ 069; these compounds maintain the kinase in an inactive conformation and inhibit autophosphorylation. SUBUNIT: Monomer. Homodimer after ligand binding. Interacts predominantly with FGF1 and FGF2, but can also interact with FGF3, FGF4, FGF6, FGF7, FGF8, FGF9, FGF10, FGF17, FGF18 and FGF22 (in vitro). Ligand specificity is determined by tissue-specific expression of isoforms, and differences in the third Ig-like domain are crucial for ligand specificity. Isoform 1 has high affinity for FGF1 and FGF2, but low affinity for FGF7. Isoform 3 has high affinity for FGF1 and FGF7, and has much higher affinity for FGF7 than isoform 1 (in vitro). Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB increases the affinity for FGF19 and FGF21. Interacts with PLCG1, GRB2 and PAK4. DOMAIN: The second and third Ig-like domains directly interact with fibroblast growth factors (FGF) and heparan sulfate proteoglycans. Alternative splicing events affecting the third Ig- like domain are crucial for ligand selectivity. DISEASE: Crouzon syndrome (CS) OMIM: An autosomal dominant syndrome characterized by craniosynostosis, hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism. is caused by mutations affecting the gene represented in this entry. DISEASE: Jackson-Weiss syndrome (JWS) OMIM: An autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence. mutations affecting the gene represented in this entry. DISEASE: Apert syndrome (APRS) OMIM: A syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations. mutations affecting the gene represented in this entry. DISEASE: Pfeiffer syndrome (PS) OMIM: A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3). disease is caused by mutations affecting the gene represented in this entry. DISEASE: Beare-Stevenson cutis gyrata syndrome (BSTVS) OMIM: An autosomal dominant disease characterized by craniofacial anomalies, particularly craniosynostosis, and ear defects, cutis gyrata, acanthosis nigricans, anogenital anomalies, skin tags, and prominent umbilical stump. The skin furrows have a corrugated appearance and are widespread. Cutis gyrata variably affects the scalp, forehead, face, preauricular area, neck, trunk, hands, and feet. mutations affecting the gene represented in this entry. DISEASE: Familial scaphocephaly syndrome (FSPC) OMIM: An autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation. Note=The disease is caused by mutations affecting the gene represented in this entry. DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS) OMIM: An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed. Note=The disease is caused by mutations affecting the gene represented in this entry. DISEASE: Antley-Bixler syndrome, without genital anomalies or disordered steroidogenesis (ABS2) OMIM: A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported. mutations affecting the gene represented in this entry. DISEASE: Bent bone dysplasia syndrome (BBDS) OMIM: A perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia. mutations affecting the gene represented in this entry.|
|UniProt features for FGFR2_HUMAN » Fibroblast growth factor receptor 2|
SIGNAL 1 21 Potential. |
CHAIN 22 821 Fibroblast growth factor receptor 2.
DOMAIN 25 125 Ig-like C2-type 1.
DOMAIN 154 247 Ig-like C2-type 2.
DOMAIN 256 358 Ig-like C2-type 3.
DOMAIN 481 770 Protein kinase.
REGION 161 178 Heparin-binding.
ACT_SITE 626 626 Proton acceptor.
DISULFID 62 107 By similarity.
DISULFID 179 231
DISULFID 278 342
|Amino Acid Sequence for FGFR2_HUMAN » Fibroblast growth factor receptor 2|
|MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEEYL DLSQPLEQYS PSYPDTRSSC SSGDDSVFSP DPMPYEPCLP QYPHINGSVK T|